Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity

Elsa Brunet‐Ratnasingham, Sacha Morin, Haley E. Randolph, Marjorie Labrecque, Justin Bélair, Raphaël Lima-Barbosa, Amélie Pagliuzza, Lorie Marchitto, Michael Hultström, Julia Niessl, Rose Cloutier, Alina Maria Sreng Flores, Nathalie Brassard, Mehdi Benlarbi, Jérémie Prévost, Shilei Ding, Sai Priya Anand, Gérémy Sannier, Eric Bareke, Hugo Zeberg, Miklós Lipcsey, Robert Frithiof, Anders Larsson, Sirui Zhou, Tomoko Nakanishi, David Morrison, Dani Vézina, Catherine Bourassa, Gabrielle Gendron‐Lepage, Halima Medjahed, Floriane Point, Jonathan Richard, Catherine Larochelle, Alexandre Prat, Nathalie Arbour, Madéleine Durand, J. Brent Richards, Kevin R. Moon, Nicolas Chomont, Andrés Finzi, Martine Tétreault, Luis B. Barreiro, Guy Wolf, Daniel E. KaufmannmedRxiv 2023 · DOI

Introduction

The clinical progression of COVID-19 is notoriously heterogeneous. While factors like plasma RNAemia, delayed antibody responses, and systemic inflammation are known predictors of poor outcomes, the biological mechanisms linking these features remain poorly understood. This research moves beyond broad clinical classifications—such as "critically ill"—to identify specific molecular "endotypes" that define patient trajectories and survival.

Defining Molecular Endotypes

To understand the diversity of immune responses, researchers performed a multi-omic longitudinal analysis of 782 plasma samples from 318 hospitalized patients across discovery and validation cohorts. Using k-means clustering on 14 early biological markers—including viral RNA levels, cytokines, tissue damage markers, and antibody isotypes—the study identified four distinct patient clusters.

Crucially, patients requiring mechanical ventilation (critically ill) were split into two biologically distinct groups:

  • Cluster 1: Characterized by high fatality rates (50% within 60 days) and delayed antibody production.
  • Cluster 2: Characterized by a good prognosis and early, robust antibody responses.

Non-critical survivors were similarly divided into Cluster 3 (delayed antibody response) and Cluster 4 (high antibody response). These findings suggest that clinical severity alone does not capture the underlying molecular state of the patient.

The Interferon Paradox in COVID-19

The most striking finding of the study is the presence of an "interferon paradox." In typical viral infections, Type I and II interferons (IFNs) are essential early antiviral defenses. However, in murine models of chronic infection, sustained IFN signaling has been shown to suppress adaptive immunity.

This study provides evidence that a similar mechanism occurs in humans with severe COVID-19. Patients in the low-antibody clusters (Clusters 1 and 3) exhibited sustained IFN-alpha and IFN-gamma signatures. Unlike survivors who showed a timely "drop" in IFN signaling, these patients maintained high IFN levels that negatively correlated with the development of adaptive immunity.

Impact on Adaptive Immunity

The sustained IFN signaling was found to interfere directly with the maturation of the virus-specific immune response. Key findings include:

  • Antibody Kinetics: Clusters 2 and 4 reached 50% of their maximum antibody levels before Day 11. In contrast, Cluster 1 reached this milestone at Day 13, and Cluster 3 was delayed until Day 17.
  • Cellular Responses: High single-sample IFN (ssIFN) scores strongly correlated with lower frequencies of RBD-specific B cells and CD4+ T cells.
  • Correlation Strength: The ssIFN score showed a significant negative correlation with contemporaneous RBD-specific IgG levels (Sr = -0.542, p < 0.0001).

Interestingly, while B cell and CD4+ T cell responses were hindered, CD8+ T cell frequencies appeared less affected by the sustained IFN environment.

Transcriptomic Signatures and Clinical Implications

Transcriptomic analysis revealed that the high-fatality Cluster 1 was uniquely enriched for signatures associated with TGFβ and mTOR signaling. This suggests that by the time these patients reach a critical state (around Day 8 post-symptom onset), a "pathogenic inflammatory cascade" is already well-established.

These insights have significant therapeutic implications. For patients in Cluster 1, traditional treatments like monoclonal antibodies may have a narrow window of efficacy because the adaptive response is already stalled. Furthermore, the data suggests a counterintuitive therapeutic approach: for a subset of patients, blocking IFN pathways—rather than supplementing them—might be necessary to allow the adaptive immune system to recover and clear the virus.

Conclusion

By identifying molecular endotypes, this research clarifies why some patients succumb to COVID-19 despite intensive clinical care. The "interferon paradox" highlights a critical failure point where the body's innate defense mechanism inadvertently delays the life-saving adaptive immune response. Future work must determine if targeted immunomodulation can break this cycle and improve outcomes for the most at-risk patients.

Summary updated

Abstract

SUMMARY Plasma RNAemia, delayed antibody responses and inflammation predict COVID-19 outcomes, but the mechanisms underlying these immunovirological patterns are poorly understood. We profile 782 longitudinal plasma samples from 318 hospitalized COVID-19 patients. Integrated analysis using k-means reveal four patient clusters in a discovery cohort: mechanically ventilated critically-ill cases are subdivided into good prognosis and high-fatality clusters (reproduced in a validation cohort), while non-critical survivors are delineated by high and low antibody responses. Only the high-fatality cluster is enriched for transcriptomic signatures associated with COVID-19 severity, and each cluster has distinct RBD-specific antibody elicitation kinetics. Both critical and non-critical clusters with delayed antibody responses exhibit sustained IFN signatures, which negatively correlate with contemporaneous RBD-specific IgG levels and absolute SARS-CoV-2-specific B and CD4 + T cell frequencies. These data suggest that the “Interferon paradox” previously described in murine LCMV models is operative in COVID-19, with excessive IFN signaling delaying development of adaptive virus-specific immunity.
BibTeX
@misc{brunetratnasingham2023sustained,
  author = {Elsa Brunet‐Ratnasingham and Sacha Morin and Haley E. Randolph and Marjorie Labrecque and Justin Bélair and Raphaël Lima-Barbosa and Amélie Pagliuzza and Lorie Marchitto and Michael Hultström and Julia Niessl and Rose Cloutier and Alina Maria Sreng Flores and Nathalie Brassard and Mehdi Benlarbi and Jérémie Prévost and Shilei Ding and Sai Priya Anand and Gérémy Sannier and Eric Bareke and Hugo Zeberg and Miklós Lipcsey and Robert Frithiof and Anders Larsson and Sirui Zhou and Tomoko Nakanishi and David Morrison and Dani Vézina and Catherine Bourassa and Gabrielle Gendron‐Lepage and Halima Medjahed and Floriane Point and Jonathan Richard and Catherine Larochelle and Alexandre Prat and Nathalie Arbour and Madéleine Durand and J. Brent Richards and Kevin R. Moon and Nicolas Chomont and Andrés Finzi and Martine Tétreault and Luis B. Barreiro and Guy Wolf and Daniel E. Kaufmann},
  title = {{Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity}},
  year = {2023},
  doi = {10.1101/2023.06.14.23290814},
  howpublished = {medRxiv},
}
Figure